Single-cell Omics Market Analysis

Single-Cell Omics Segmentation

Application (Immunology, Neurology, Oncology, Cell Biology)

In 2037, the oncology sector is estimated to account for 46% share of the global single-cell omics market. The growth of the segment can be attributed to the rise in the number of gene therapy trials focusing on genomics in cancer care. As of 2022, over 770 of the over 1,200 active clinical studies for cell and gene therapies were in oncology. Single-cell omics enable the identification of specific gene expression patterns or genetic alterations associated with therapeutic response or resistance. By profiling individual cancer cells, researchers can identify biomarkers that predict the likelihood of response to gene therapy. Furthermore, rising investment in cancer treatment has driven the segment’s growth. By building state-of-the-art cancer treatment centers and ensuring proper testing, screening, and treatment of cancers impacted by the COVID-19 pandemic, the Australian Government is investing USD 614 million in services

End User (Pharmaceutical & Biotechnology Companies, Research Organization, Hospitals)

The research organization segment  is projected to hold around 55% share of the global single-cell omics market in the year 2037. The segment will expand at a notable CAGR over the projected time period. Rising investment by private sectors to accelerate the research in the research facilities. For instance, Schmidt Futures allocated USD 550 million to the latest research facility aimed at growing single-cell proteomics technologies in March 2023. Increased investment in research facilities allows for the establishment of advanced infrastructure dedicated to single-cell omics research. This includes the procurement of advanced equipment, such as high-throughput sequencers, single-cell isolation systems, and imaging platforms.

Our in-depth analysis of the global single-cell omics market includes the following segments: